Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report) and Connect Biopharma (NASDAQ:CNTB – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, valuation, dividends and profitability.
Analyst Ratings
This is a summary of current ratings for Artiva Biotherapeutics and Connect Biopharma, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Artiva Biotherapeutics | 1 | 0 | 4 | 1 | 2.83 |
| Connect Biopharma | 1 | 0 | 8 | 0 | 2.78 |
Artiva Biotherapeutics currently has a consensus price target of $39.00, indicating a potential upside of 529.03%. Connect Biopharma has a consensus price target of $5.88, indicating a potential upside of 670.90%. Given Connect Biopharma’s higher probable upside, analysts clearly believe Connect Biopharma is more favorable than Artiva Biotherapeutics.
Profitability
This table compares Artiva Biotherapeutics and Connect Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Artiva Biotherapeutics | N/A | -53.86% | -48.16% |
| Connect Biopharma | N/A | -165.41% | -121.58% |
Volatility & Risk
Artiva Biotherapeutics has a beta of 2.4, indicating that its share price is 140% more volatile than the S&P 500. Comparatively, Connect Biopharma has a beta of -0.16, indicating that its share price is 116% less volatile than the S&P 500.
Earnings & Valuation
This table compares Artiva Biotherapeutics and Connect Biopharma”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Artiva Biotherapeutics | $250,000.00 | 1,212.47 | -$83.86 million | ($3.30) | -1.88 |
| Connect Biopharma | $60,000.00 | 799.82 | -$55.48 million | ($1.19) | -0.64 |
Connect Biopharma has lower revenue, but higher earnings than Artiva Biotherapeutics. Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
58.7% of Connect Biopharma shares are owned by institutional investors. 1.8% of Artiva Biotherapeutics shares are owned by insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Artiva Biotherapeutics beats Connect Biopharma on 7 of the 13 factors compared between the two stocks.
About Artiva Biotherapeutics
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
About Connect Biopharma
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.
Receive News & Ratings for Artiva Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artiva Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
